Prevalence of beta-lactam nonsusceptible Gram-negative bacilli and use and interpretation of current susceptibility breakpoints: A survey of infectious disease physicians

Diagnostic Microbiology and Infectious Disease

Volumn 71, Issue 3, 2011, Pages 316-319

  Kallen, Alexander J ^a   Beekmann, Susan E ^b   Limbago, Brandi ^a   Lentnek, Arnold L ^c   Polgreen, Philip M ^b   Patel, Jean ^a   Srinivasan, Arjun ^a  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c Infectious Diseases Medical Practice of New York   (United States)

Author keywords

Antimicrobial resistance; Antimicrobial susceptibility; Gram negative bacilli

Indexed keywords

BETA LACTAM ANTIBIOTIC; POLYMYXIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL COLONIZATION; CLINICAL DECISION MAKING; CONSENSUS; CONTROLLED STUDY; DRUG USE; ENTEROBACTERIACEAE; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; HUMAN; INFECTION PREVENTION; PHYSICIAN ATTITUDE; PREVALENCE; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; BETA-LACTAMS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; HEALTH SURVEYS; HUMANS; MICROBIAL SENSITIVITY TESTS; PHYSICIANS; PREVALENCE; PUBLIC HEALTH;

EID: 80053897220     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2011.07.013     Document Type: Article

References (10)

1. Bhavnani S.M., Ambrose P.G., Craig W.A., Dudley M.N., Jones R.N. Outcomes evaluation of patients with ESBL- and non-ESBL-producing Escherichia coli and Klebsiella species as defined by CLSI references methods; report from SENTRY Antimicrobial Surveillance Program. Diagn. Microbiol. Infect. Dis. 2006, 54:231-236.
2. Bilavsky E., Schwaber M.J., Carmeli Y. How to stem the tide of carbapenemase-producing Enterobacteriaceae? proactive versus reactive strategies. Curr. Opin. Infect Dis. 2010, 23:32-331.
3. Guidance for control of infections with carbapenem-resistant or carbapenemase-producing Enterobacteriaceae in acute care facilities. Morb. Mort. Wkly. Rpt. 2009, 58:256-260. Centers for Disease Control and Prevention (CDC).
4. Performance standards for antimicrobial susceptibility testing. 20th informational supplement. (M100-S20) 2010, Clinical Laboratory Standards Institute (CLSI), CLSI, Wayne, PA.
5. Performance standards for antimicrobial susceptibility testing. 20th informational supplement (June 2010 update) 2010, Clinical Laboratory Standards Institute (CLSI), CLSI, Wayne, PA.
6. Hidron A.I., Edwards J.R., Patel J., Horan T.C., Sievert D.M., Pollock D.A., Fridkin S.K. Antimicrobial-resistant pathogens associated with healthcare-associated infections: annual survey of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp. Epidemiol. 2008, 29:996-1011.
7. Jenkins SG, (2010) CLSI changes for cephalosporin/Enterobacteriaceae breakpoints "PRO". Clinical Microbiology issues Update - August 2010. Available at: http://www.asm.org/images/pdf/Clinical/ebslentericbreakpointclsichanges2010pro.pdf.
8. Paterson D.L., Ko W., Von Gottenberg A., Casellas J.M., Mulazimoglu L., Klugman K.P., Bonomo R.A., Rice L.B., McCormack J.G., Yu V.L. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J. Clin. Microbiol. 2001, 39:2206-2212.
9. Schreckenberger PC, (2010) CLSI changes for cephalosporin/Enterobacteriaceae breakpoints "CON". Clinical Microbiology issues Update - August 2010. Available at: http://www.asm.org/images/pdf/Clinical/ebslentericbreakpointclsichanges2010con.pdf.
10. Wong-Beringer A., Hindler J., Loeloff M., Queenan A.M., Lee N., Pegues D.A., Quinn J.P., Bush K. Molecular correlation for the treatment outcomes in bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae with reduced susceptibility to ceftazidime. Clin. Infect. Dis. 2002, 34:135-146.